The Bilirubin Blues: Plasma Exchange for Bilirubin Nephropathy

Introduction: Bilirubin or cholemic nephropathy is a rare but serious complication of severe hyperbilirubinemia. It is characterized by acute kidney injury (AKI) caused by bilirubin-induced tubular toxicity. While supportive care is the standard treatment, therapeutic plasma exchange (TPE) has emerged as a potential intervention to reduce bilirubin levels and improve renal outcomes. Case Description: A 28-year-old male with a history of alcohol abuse and a recent admission for acute alcoholic hepatitis presented with worsening abdominal pain. He was being evaluated for transfer to a liver transplant center. On admission, laboratory testing revealed a creatinine of 15 mg/dL and total bilirubin of 20 mg/dL. He had previously failed to respond to Terlipressin for presumed hepatorenal syndrome. Due to worsening renal function, hemodialysis was initiated. Given the strong clinical suspicion for bilirubin nephropathy as the cause of AKI, TPE was initiated. The patient underwent 3 sessions of TPE, which led to marked improvement in both renal and hepatic function. Discussion: TPE is an extracorporeal therapy that removes large molecular weight substances, such as bilirubin, from the bloodstream. While it remains experimental in the setting of bilirubin nephropathy, it may be beneficial in cases of severe hyperbilirubinemia associated AKI that are resistant to conventional therapies. This case highlights the importance of considering bilirubin nephropathy in patients with liver dysfunction and unexplained AKI. Though not yet standard of care, TPE may offer a promising therapeutic option for improving renal outcomes by rapidly reducing toxic bilirubin levels. Comprehensive Metabolic Panel - Laboratory Admission Discharge BUN 156 mg/dL 23 mg/dL Creatinine 15 mg/dL 1.16 mg/dL Sodium 130 mEq/L 145 mEq/L Potassium 4.2 mEq/L 4.3 mEq/L Chloride 93 mEq/L 108 mEq/L CO2 15 mEq/L 24 mEq/L Anion Gap 28 mEq/L 13 mEq/L Albumin 3.86 g/dL 3.90 g/dL Total Bilirubin 20 mg/dL 4.6 mg/dL Alkaline Phosphatase 199 U/L 235 U/L Aspartate aminotransferase 114 U/L 102 U/L Alanine aminotransferase 771 U/L 253 U/L

Authors

Institutions

Publication Details

Journal
Journal of the American Society of Nephrology
Published
2025-10-01
DOI
https://doi.org/10.1681/asn.2025htcby9zh
Primary Topic
Neonatal Health and Biochemistry
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The Bilirubin Blues: Plasma Exchange for Bilirubin Nephropathy

Umair Ahmed, José Padilla, Assem Sherieh, Pedro Pablo García‐Luna et al.
Journal of the American Society of Nephrology
Neonatal Health and Biochemistry
article

The Bilirubin Blues: Plasma Exchange for Bilirubin Nephropathy

Umair Ahmed, José Padilla, Assem Sherieh, Pedro Pablo García‐Luna, Andrew Lurie, Jennifer Trube
article en

Abstract

Introduction: Bilirubin or cholemic nephropathy is a rare but serious complication of severe hyperbilirubinemia. It is characterized by acute kidney injury (AKI) caused by bilirubin-induced tubular toxicity. While supportive care is the standard treatment, therapeutic plasma exchange (TPE) has emerged as a potential intervention to reduce bilirubin levels and improve renal outcomes. Case Description: A 28-year-old male with a history of alcohol abuse and a recent admission for acute alcoholic hepatitis presented with worsening abdominal pain. He was being evaluated for transfer to a liver transplant center. On admission, laboratory testing revealed a creatinine of 15 mg/dL and total bilirubin of 20 mg/dL. He had previously failed to respond to Terlipressin for presumed hepatorenal syndrome. Due to worsening renal function, hemodialysis was initiated. Given the strong clinical suspicion for bilirubin nephropathy as the cause of AKI, TPE was initiated. The patient underwent 3 sessions of TPE, which led to marked improvement in both renal and hepatic function. Discussion: TPE is an extracorporeal therapy that removes large molecular weight substances, such as bilirubin, from the bloodstream. While it remains experimental in the setting of bilirubin nephropathy, it may be beneficial in cases of severe hyperbilirubinemia associated AKI that are resistant to conventional therapies. This case highlights the importance of considering bilirubin nephropathy in patients with liver dysfunction and unexplained AKI. Though not yet standard of care, TPE may offer a promising therapeutic option for improving renal outcomes by rapidly reducing toxic bilirubin levels. Comprehensive Metabolic Panel - Laboratory Admission Discharge BUN 156 mg/dL 23 mg/dL Creatinine 15 mg/dL 1.16 mg/dL Sodium 130 mEq/L 145 mEq/L Potassium 4.2 mEq/L 4.3 mEq/L Chloride 93 mEq/L 108 mEq/L CO2 15 mEq/L 24 mEq/L Anion Gap 28 mEq/L 13 mEq/L Albumin 3.86 g/dL 3.90 g/dL Total Bilirubin 20 mg/dL 4.6 mg/dL Alkaline Phosphatase 199 U/L 235 U/L Aspartate aminotransferase 114 U/L 102 U/L Alanine aminotransferase 771 U/L 253 U/L

Journal of the American Society of NephrologyVol. 36(10S)
Lakeland Regional Medical Center (US)
Openalex Percentile: Top 52%
Neonatal Health and Biochemistry
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.